Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note released on Tuesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH opened at $0.04 on Tuesday. The firm has a market capitalization of $428,155.00, a P/E ratio of -0.04 and a beta of 0.73. Bellerophon Therapeutics has a one year low of $0.03 and a one year high of $0.52. The company has a fifty day moving average price of $0.05 and a 200-day moving average price of $0.05.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.